

(Ala13)-Apelin-13

Cat. No.:	HY-P3162
CAS No.:	568565-11-7
Molecular Formula:	C ₆₃ H ₁₀₇ N ₂₃ O ₁₆ S
Molecular Weight:	1474.73
Sequence:	Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Ala
Sequence Shortening:	QRPRLSHKGMPMA
Target:	Apelin Receptor (APJ)
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	(Ala13)-Apelin-13 is a potent apelin receptors (APJ) antagonist. (Ala13)-Apelin-13 inhibits gastric motility through vagal cholinergic pathway ^[1] .								
In Vivo	<p>(Ala13)-Apelin-13 (1-300 pmol/60 nl; microinjected into the DVC) decreases gastric tone and motility in a dose-dependent manner in rats^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table> <tr> <td>Animal Model:</td> <td>250-300 g, Sprague-Dawley rats^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1-300 pmol/60 nl</td> </tr> <tr> <td>Administration:</td> <td>Microinjected into the DVC (dorsal vagal complex (DVC))</td> </tr> <tr> <td>Result:</td> <td>Decreased gastric tone and motility in a dose-dependent manner with D50 ≈ 27 pmol for both antrum and corpus.</td> </tr> </table>	Animal Model:	250-300 g, Sprague-Dawley rats ^[1]	Dosage:	1-300 pmol/60 nl	Administration:	Microinjected into the DVC (dorsal vagal complex (DVC))	Result:	Decreased gastric tone and motility in a dose-dependent manner with D50 ≈ 27 pmol for both antrum and corpus.
Animal Model:	250-300 g, Sprague-Dawley rats ^[1]								
Dosage:	1-300 pmol/60 nl								
Administration:	Microinjected into the DVC (dorsal vagal complex (DVC))								
Result:	Decreased gastric tone and motility in a dose-dependent manner with D50 ≈ 27 pmol for both antrum and corpus.								

REFERENCES

- [1]. Bülbül M, et al. Apelin-13 inhibits gastric motility through vagal cholinergic pathway in rats. *Am J Physiol Gastrointest Liver Physiol*. 2018 Feb 1;314(2):G201-G210.
- [2]. O'Harte FPM, et al. Acylated apelin-13 amide analogues exhibit enzyme resistance and prolonged insulin releasing, glucose lowering and anorexic properties. *Biochem Pharmacol*. 2017 Dec 15;146:165-173.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA